Early results of the TRILUMINATE trial presented at the EuroPCR conference will support a CE mark for a version of MitraClip adapted to reduce tricuspid valve regurgitation.
Initial results from the TRILUMINATE trial show Abbott Laboratories Inc.’s transcatheter tricuspid valve repair (TTVR) system can significantly reduce tricuspid regurgitation and improve heart failure symptoms.
Tricuspid regurgitation, a backward flow of blood from the heart’s right ventricle through the tricuspid valve into the right atrium, can eventually cause right-heart failure. About 3% of people over...
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.
